Healixia News - page 43

April 6, 2020

Updated guidelines for the labelling and packaging of medicinal products for human use

Heard from FAMHP

Marketing authorisation holders of a medicinal product for human use are required to follow certain guidelines for the labelling and packaging of medicinal products. These guidelines have recently been updated.

April 6, 2020

Coronavirus: details of the measures taken by the FAMHP to avoid shortages of medicines

Heard from FAMHP

Details van de maatregelen die het FAGG heeft genomen om tekorten aan geneesmiddelen te vermijden.

Détail des mesures prises par l’AFMPS pour éviter les pénuries de médicaments.

April 6, 2020

Coronavirus: hydroxychloroquine and chloroquine, beware of their elimination half-life and of the risk of drug interactions

Heard from FAMHP

Flash VIG-news: hydroxychloroquine en chloroquine, pas op voor hun eliminatie-halfwaardetijd en voor het risico op geneesmiddeleninteracties

Flash VIG-news : hydroxychloroquine et chloroquine, attention à leur demi-vie d’élimination et aux risques d’interactions médicamenteuses

April 6, 2020

Coronavirus: hydroxychloroquine, chloroquine and Kaletra (lopinavir + ritonavir) are distributed in a controlled way for a better follow-up of the treatment.

Heard from FAMHP

Coronavirus: hydroxychloroquine, chloroquine en Kaletra (lopinavir + ritonavir) worden voor een betere opvolging van de behandeling op een gecontroleerde manier verdeeld in België

Coronavirus : hydroxychloroquine, chloroquine et Kaletra (lopinavir + ritonavir) sont distribués de manière contrôlée en Belgique, pour une surveillance accrue des traitements

April 6, 2020

Coronavirus: measures taken by the FAMHP to avoid drug shortages

Heard from FAMHP

Coronavirus: maatregelen van het FAGG om geneesmiddelentekorten te vermijden

Coronavirus : mesures de l’AFMPS pour éviter les pénuries de médicaments

April 6, 2020

Coronavirus: guidelines for checking the compliance and suitability of certain surgical face masks

Heard from FAMHP

The FAMHP issues guidelines for checking the compliance and suitability of surgical face masks The guidelines are for companies not producing in accordance with European standards and for healthcare establishments and authorities ordering the masks.

April 6, 2020

Nitrosamines in medicinal products: report results of risk assessments for impurities

Heard from FAMHP

Update 30.03.2020: the deadline for the first part of the risk assessment has been prolonged from 26th March 2020 to the 1st of Octobre 2020.

Update 30.03.2020: the deadline for the first part of the risk assessment has been prolonged from 26th March 2020 to the 1st of Octobre 2020.

Early October 2019, the European Medicines Agency (EMA), together with the European medicines authorities, including the FAMHP, asked marketing authorisation holders to perform a risk assessment on the presence of nitrosamines as a precaution. The results of these risk assessments can now be reported.

March 26, 2020

Coronavirus: FAMHP seizes postal parcels containing counterfeit and other illegal medicines against COVID-19

Heard from FAMHP

Coronavirus: FAGG neemt postpakketten met namaak en andere illegale geneesmiddelen tegen COVID-19 in beslag

Coronavirus : l'AFMPS saisit des colis postaux contenant des médicaments contrefaits et d’autres médicaments illégaux contre le COVID-19

March 26, 2020

Coronavirus: Belgian guideline for the management of clinical trials during the coronavirus pandemic

Heard from FAMHP

A national guideline is available to complement European guidelines for the management of clinical trials during the coronavirus pandemic.

March 25, 2020

Urgent mesures from the Luxembourg Authorities

Here you will find an order which regulates the supply of medicines in Luxembourg and a general ban on the export of medicines.